Form D · Biotechnology
Andes AG, Inc.
Alameda, CA · CIK 0001877638
Offering snapshot reported Oct 28, 2022 · SEC filing
- Reported sold
- $13M Offering amount: $15M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 28, 2022 | Initial | $12,999,983 | No comparison | 17 | SEC filing |
| Aug 11, 2021 | Initial | $15,050,214 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-463139
Source: Form D, filed Oct 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pablo Fernandez | Director |
| Gonzalo Fuenzalida Meriz | Director, Executive |
| Phil Grayeski | Director |
| Brett Morris | Director |
| Derek Norman | Director |
| Pablo Prato | Director |
| Sarah Sclarsic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Andes Ag, Inc. 1210 Marina Village Pkwy
Alameda, CA, 94501
Alameda, CA, 94501